SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) (TA834)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 October 2022
Palforzia for treating peanut allergy in children and young people (TA769)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 June 2021
Omalizumab for treating severe persistent allergic asthma (TA278)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2013
Pharmalgen for the treatment of bee and wasp venom allergy (TA246)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 February 2012
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 9 July 2024
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
WP1048 for treating grass pollen allergy in people aged 18 to 60 TS ID 10467Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years TS ID 11885Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC